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Subanesthetic Ketamine Infusion in Reducing Symptoms of End-of-Life Depression: A Case Report
Leanne Groban, MD and Kavita Sharma, MD, FAAHPM
1. Distinguish between major depression, anticipatory grief
and hypoactive delirium in terminally ill patients with endstage heart disease.
Clinical depression is a treatable condition, yet often
overlooked in terminally ill patients because it may be
misconstrued as anticipatory (or preparatory) grief. Because
failure to treat impairs quality of life and contributes to total
suffering, it is imperative that it is recognized and managed,
even at the end of life. Feelings of generalized guilt,
hopelessness, worthlessness, inability to feel pleasure, lack of
response to social support and suicidal ideation are key factors
that differentiate depression from grief. Anticipatory grief is
associated with feelings of sadness, described as “good and bad
days”, and a positive response to social supports. Unlike the
depressed patient, a grieving patient’s hope often shifts over the
course of the terminal illness from hoping for a cure or life
prolongation to hoping for a good death. Another condition
confused with depression in a patient with serious illness is
hypoactive delirium. While depression and delirium may
present with overlapping symptoms such as slow mentation,
decreased concentration, withdrawal, apathy, changes in sleep
and appetite, the timeline of symptom onset and progression is
key to their differentiation; intermittent to chronic is often
observed with depression whereas an acute or subacute onset is
linked to delirium. Screening tests such as the Patient Health
Questionnaire (PHQ-4) and 3DCAM are useful in
distinguishing between these common sources of emotional and
physical suffering at the end of life.
•
•
•

Symptoms of Depression in Heart Failure Patients “SIGECAPS”

Sleep disorder
Interest deficit
Guilt
Energy deficit
Concentration deficit
Appetite disorder
Psychomotor retardation or agitation
Suicidality
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2. Categorize antidepressants used for patients with serious
illness, emphasizing pros and cons in the context of HF.
Treating depression at the end of life may alleviate both
physical and psychological suffering and improve distressing
symptoms for both patients and their caregivers. In a
longitudinal study of patients with heart failure, worsening
symptoms of depression were associated with increased
hospitalization for heart disease. In another study, fewer than
half with advanced heart disease received treatment for
depression. Selective serotonin reuptake inhibitors (SSRIscitalopram, escitalopram, fluoxetine, paroxetine, sertraline) and
Bupropion (NE-Dopamine reuptake inhibitor) are probably the
safest for patients with heart disease, with the need for increased
caution when paired with the antibiotic erythromycin due to
increased risk of arrhythmias. Serotonin-norepinephrine
reuptake inhibitors (SNRIs – duloxetine, venlafaxine) may
increase blood pressure. Tricyclic antidepressants (TCAsamitriptyline, desipramine, doxepin, nortriptyline) may cause
orthostatic hypotension, arrhythmias and QT prolongation.
When life expectancy is short (<6 weeks), adding
psychostimulants (methylphenidate, modafinil) for hypoactive
depressive symptoms (e.g., fatigue, anorexia, lethargy) should
only be considered in noncardiac patients. Tachycardia from
psychostimulants can lead to cardiac decompensation in those

Chemical basis for depression is presumed
to be linked to decreased levels of
neurotransmitters -serotonin, dopamine,
and norepinephrine (NE).

with heart disease. Low dose mirtazapine is helpful in patients
with insomnia, due to it antihistamine effects, and for weight
gain. Trazadone may improve sleep quality and nocturnal
awakening; yet can also promote orthostasis.
If depression persists, augmentation of SSRIs with 2nd
generation antipsychotics may be considered, yet with caution
given that quetiapine has been linked to hypotension and
olanzapine, quetiapine, and risperidone to QTc prolongation. If
depression emerges in bipolar disorder, SSRI and SNRI’s can
lead to exacerbated mania, and should be avoided. Abrupt
discontinuation of SSRIs can lead to withdrawal symptoms and
rebound depression; thus, tapering is recommended.

3. Recognize the therapeutic potential and underlying
biological mechanisms for the use of low-dose ketamine
infusion in the management of treatment-resistant
depression.
Patients who do not respond to two or more antidepressants are
classified as treatment resistant-depression and are patients of
choice for ketamine therapy. Evidence suggests that N-methylD-aspartate (NMDA) receptor antagonism by ketamine
produces rapid and sustained antidepressant activity in resistant
patients. A distinctive feature of major depression is the
manifestation of suicidal thoughts and attempts. Although the
brain circuitry responsible for the formation of suicidal ideas
and the execution of suicidal acts is not known, several studies
demonstrate that 0.5 mg/kg of ketamine infused over 40 min
versus placebo or versus midazolam, reduced suicidal ideation
and depressive symptoms. It is interesting to posit that the
dissociative effect of ketamine triggers some mechanism that
interferes with the generation of nightmares in the CNS or
interferes in the transition between suicide and its realization.
When the effect of ketamine on the reduction of nocturnal
wakefulness may be involved in reduced nightmare remains
speculative. Indeed, it is curious that in healthy individuals
without depression, ketamine has caused unpleasant dreams. In
general, it has been suggested that the response to ketamine is
closely related to the emotional state of the individual and the
extent of glutamate transmission – leading to differences in both
its rapid and prolonged effects. It is worth noting that when used
as an anesthetic (where dosing is 7 times higher than that for the
management of depression), ketamine increases blood pressure,
heart rate, and cardiac output - and, thus, is frequently the agent
used for induction of anesthesia in those at-risk for hypotension.
•

•

•
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